Find a Parkview Health Clinical Trial
7 results found
Current Studies
Primary Outcome Measures: *Safety of patient management pathway - Proportion of medication interventions with associated medication intervention related serious adverse events (Time Frame: Up to 3 years) *The proportion of medication interventions with one or more associated medication...
PRIMARY OBJECTIVE To assess the effect of in-hospital initiation of dapagliflozin, as compared with placebo, on the clinical outcomes of cardiovascular death or worsening heart failure in patients who have been stabilized during hospitalization for acute heart failure. To evaluate the safety and...
Primary Objective: To determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the...
To offer NODE-301, NODE-302 and NODE-303 subjects continued access to Etripamil
Primary Objective: * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of death from coronary heart disease, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or...
To evaluate the diagnostic accuracy of a plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRCT) software device (ElucidVivoTM) as compared to invasive fractional flow reserve (FFR) in patients who underwent clinically indicated CCTA and invasive FFR.
Primary Outcome Measures: The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene. Secondoary Outcome...